JPWO2020223702A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020223702A5 JPWO2020223702A5 JP2021565064A JP2021565064A JPWO2020223702A5 JP WO2020223702 A5 JPWO2020223702 A5 JP WO2020223702A5 JP 2021565064 A JP2021565064 A JP 2021565064A JP 2021565064 A JP2021565064 A JP 2021565064A JP WO2020223702 A5 JPWO2020223702 A5 JP WO2020223702A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- galectin
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841732P | 2019-05-01 | 2019-05-01 | |
| US62/841,732 | 2019-05-01 | ||
| PCT/US2020/031181 WO2020223702A1 (en) | 2019-05-01 | 2020-05-01 | Anti-galectin-9 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531408A JP2022531408A (ja) | 2022-07-06 |
| JPWO2020223702A5 true JPWO2020223702A5 (enExample) | 2023-05-11 |
| JP7581238B2 JP7581238B2 (ja) | 2024-11-12 |
Family
ID=73029403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565064A Active JP7581238B2 (ja) | 2019-05-01 | 2020-05-01 | 抗ガレクチン９抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220178930A1 (enExample) |
| EP (1) | EP3962954A4 (enExample) |
| JP (1) | JP7581238B2 (enExample) |
| CN (2) | CN119033928A (enExample) |
| AU (1) | AU2020266677A1 (enExample) |
| CA (1) | CA3138863A1 (enExample) |
| SG (1) | SG11202112112UA (enExample) |
| WO (2) | WO2020223702A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202003652QA (en) | 2017-10-27 | 2020-05-28 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
| EP3962954A4 (en) * | 2019-05-01 | 2023-01-18 | New York University | ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF |
| US20240109968A1 (en) * | 2020-11-20 | 2024-04-04 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| AU2022266821A1 (en) * | 2021-04-30 | 2023-11-09 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and therapeutic uses thereof |
| WO2022232653A1 (en) * | 2021-04-30 | 2022-11-03 | Puretech Lyt, Inc. | Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy |
| CA3233331A1 (en) * | 2021-10-01 | 2023-04-06 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and therapeutic uses thereof |
| JP2025522729A (ja) * | 2022-06-29 | 2025-07-17 | ピュアテック・エル・ワイ・ティ・インコーポレイテッド | ガレクチン－９を阻害する抗体を用いた悪性血液疾患の処置 |
| CN120585880B (zh) * | 2025-08-07 | 2025-12-09 | 四川大学华西医院 | 一种用于预防和/或治疗前列腺癌的联合用药物，其用途及药物组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2591786B1 (en) * | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| CN101120021A (zh) * | 2004-12-31 | 2008-02-06 | 基因技术公司 | 结合br3的多肽及其用途 |
| EP1973951A2 (en) * | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CN101977934B (zh) * | 2008-01-18 | 2014-09-17 | 健泰科生物技术公司 | 用于靶向k63连接的多聚遍在蛋白的方法和组合物 |
| AU2009270793A1 (en) * | 2008-07-18 | 2010-01-21 | Oragenics, Inc. | Compositions for the detection and treatment of colorectal cancer |
| AR083819A1 (es) * | 2010-11-10 | 2013-03-27 | Genentech Inc | UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL |
| CN103314102A (zh) * | 2010-12-09 | 2013-09-18 | 株式会社嘉尔药物 | 分泌半乳糖凝集素9的细胞、其制造方法及其用途 |
| FR3021970B1 (fr) * | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs |
| EP3215845A4 (en) * | 2014-11-04 | 2018-04-18 | Dana-Farber Cancer Institute, Inc. | Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses |
| US10294294B2 (en) * | 2015-09-10 | 2019-05-21 | Albert Einstein College Of Medicine | Synthetic antibodies to BAX and uses thereof |
| WO2017202962A1 (en) * | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
| US20200223924A1 (en) * | 2017-06-27 | 2020-07-16 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
| WO2019036031A2 (en) * | 2017-08-17 | 2019-02-21 | Nektar Therapeutics | IMMUNOTHERAPEUTIC METHOD FOR TUMOR TREATMENT |
| SG11202003652QA (en) * | 2017-10-27 | 2020-05-28 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
| AU2020247993A1 (en) * | 2019-03-25 | 2021-11-18 | New York University | Anti-Galectin-9 antibodies and uses thereof |
| EP3962954A4 (en) * | 2019-05-01 | 2023-01-18 | New York University | ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF |
| AU2020319899A1 (en) * | 2019-08-01 | 2022-02-24 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
| WO2022093841A1 (en) * | 2020-10-26 | 2022-05-05 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma |
| US20240109968A1 (en) * | 2020-11-20 | 2024-04-04 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| US20240043543A1 (en) * | 2020-11-20 | 2024-02-08 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| WO2022232653A1 (en) * | 2021-04-30 | 2022-11-03 | Puretech Lyt, Inc. | Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy |
| AU2022266821A1 (en) * | 2021-04-30 | 2023-11-09 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and therapeutic uses thereof |
-
2020
- 2020-05-01 EP EP20798582.1A patent/EP3962954A4/en active Pending
- 2020-05-01 CA CA3138863A patent/CA3138863A1/en active Pending
- 2020-05-01 SG SG11202112112UA patent/SG11202112112UA/en unknown
- 2020-05-01 US US17/607,879 patent/US20220178930A1/en not_active Abandoned
- 2020-05-01 WO PCT/US2020/031181 patent/WO2020223702A1/en not_active Ceased
- 2020-05-01 CN CN202411238025.5A patent/CN119033928A/zh active Pending
- 2020-05-01 CN CN202080047488.7A patent/CN114026126B/zh active Active
- 2020-05-01 JP JP2021565064A patent/JP7581238B2/ja active Active
- 2020-05-01 WO PCT/US2020/031184 patent/WO2020223704A1/en not_active Ceased
- 2020-05-01 AU AU2020266677A patent/AU2020266677A1/en active Pending
- 2020-05-01 US US17/607,878 patent/US20220185896A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| JP6283665B2 (ja) | Ｇｄ２陽性癌を治療するための方法 | |
| JP2020508317A5 (enExample) | ||
| JP2023130496A (ja) | 癌治療のための併用療法 | |
| JP2014533279A5 (enExample) | ||
| JP2019515008A5 (enExample) | ||
| KR20210149870A (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| JP2016530323A5 (enExample) | ||
| TW201902514A (zh) | Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2025026572A5 (enExample) | ||
| IL300813A (en) | LAG-3 antagonist therapy for hepatocellular carcinoma | |
| WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| JP2020507596A5 (enExample) | ||
| JPWO2019160755A5 (enExample) | ||
| JPWO2020223702A5 (enExample) | ||
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| TW201322985A (zh) | 由ＥｐＣＡＭｘＣＤ３雙特異性抗體引起之不良作用的預防 | |
| JP2020500161A5 (enExample) | ||
| WO2023147371A1 (en) | Combination therapy for hepatocellular carcinoma | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| CN118697865A (zh) | 治疗淋巴瘤的药物组合 | |
| EP4561623A1 (en) | Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies | |
| CN118871128A (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 |